Key Development
Novo Nordisk has added another cardiovascular data point to its competition with Eli Lilly — but this is real-world association, not randomized head-to-head proof of superiority.
At EASD 2026, Novo presented COMPETE SWITCH CV, a retrospective U.S. claims analysis evaluating patients with type 2 diabetes already receiving semaglutide 1 mg. The cardiovascular analysis included 185,705 adults who escalated to Ozempic 2 mg and 23,104 who switched to Mounjaro, with tirzepatide doses up to 15 mg. Escalation to semaglutide 2 mg was associated with approximately 6% lower risk of a composite of all-cause death, myocardial infarction and stroke.
The broader treatment-pattern dataset included 636,525 adults. By 720 days, 36.9% had escalated semaglutide while 5.7% had switched to tirzepatide. Among switchers, only approximately 31% reached doses of at least 10 mg. Novo explicitly acknowledged that residual confounding remains possible and that retrospective evidence demonstrates association rather than causality.
Why It Matters
- Cardiovascular outcomes are becoming a new competitive axis for incretins. A1C and weight loss are increasingly only part of the product profile.
- The reported 6% difference is relatively modest. Statistical significance does not automatically establish clinically decisive superiority.
- This is a treatment-strategy comparison, not a clean drug-versus-drug trial. Every patient began on semaglutide 1 mg; the practical question is whether to escalate semaglutide or switch therapy.
- Tirzepatide already has randomized cardiovascular evidence. In the 13,299-patient SURPASS-CVOT, tirzepatide was noninferior to dulaglutide for MACE-3, with a hazard ratio of 0.92. FDA subsequently approved Mounjaro to reduce major cardiovascular-event risk in high-risk adults with type 2 diabetes.
Healthcare Insight Analysis
Healthcare Insight believes the most important impact of COMPETE SWITCH may be on the competitive narrative, rather than clinical hierarchy.
The first stage of the GLP-1 market largely asked:
Which drug lowers A1C more?
Which drug produces more weight loss?
By 2026, those questions are no longer enough.
As multiple agents produce substantial metabolic effects, differentiation is expanding toward:
cardiovascular outcomes → renal outcomes → tolerability → persistence → convenience → price.
Semaglutide enters that contest with a substantial cardiovascular evidence base. SUSTAIN-6 reported a hazard ratio of 0.74 versus placebo for major cardiovascular events in high-risk type 2 diabetes, while the larger SOUL trial of oral semaglutide reported a hazard ratio of 0.86 versus placebo.
But those randomized trials also illustrate why COMPETE SWITCH must be interpreted carefully.
The central limitation is confounding by treatment selection.
Patients whose physicians retain semaglutide and increase the dose may systematically differ from those switched to tirzepatide. Previous response, tolerability, obesity severity, glycemic control, comorbidity, insurance restrictions and clinician preferences may influence both treatment choice and subsequent cardiovascular outcomes.
Adjustment models can reduce observed imbalance; they cannot eliminate variables that were never measured.
Dose exposure also matters.
Although tirzepatide could be titrated up to 15 mg, only around 31% of switchers reached at least 10 mg during follow-up. This means COMPETE SWITCH should not be interpreted as a comparison between fully optimized maximum-dose semaglutide and maximum-dose tirzepatide.
There is an additional methodological nuance.
The COMPETE SWITCH composite uses all-cause death, MI and stroke, whereas conventional randomized MACE-3 endpoints generally use cardiovascular death, nonfatal MI and nonfatal stroke. Its hazard ratio therefore should not be lined up numerically against SUSTAIN-6 or SURPASS-CVOT as though the endpoints were identical.
This is increasingly important as the commercial battle intensifies.
Both Novo and Lilly now have incentives to generate comparative evidence around their franchises. Real-world datasets can answer questions that RCTs may never address, but they also make study design literacy a competitive necessity for clinicians, payers and investors.
A headline saying “6% lower cardiovascular risk” is commercially powerful.
The scientific question remains more restrained:
Would the same difference persist if patients were randomized?
Today, the evidence does not answer that.
Market Implications
Novo Nordisk: strengthens the case for semaglutide dose escalation in selected patients already doing well on the molecule.
Eli Lilly: retains randomized CVOT validation and an FDA cardiovascular-risk indication for Mounjaro.
Payers: hard-outcome evidence could increasingly influence formulary decisions, but evidence hierarchy will matter as much as effect size.
Clinicians: incretin selection is becoming a multidimensional decision across glucose, weight, cardiovascular disease, kidney disease, tolerability and treatment persistence.
ANALYTICAL MATRIX
| Dimension | COMPETE SWITCH CV | Strategic Value | Limitation |
|---|---|---|---|
| Design | Retrospective RWE | Reflects clinical practice | Non-randomized |
| Population | Prior semaglutide 1 mg users | Relevant intensification question | Not treatment-naïve |
| Outcome | ~6% lower associated risk | CV differentiation signal | Modest effect size |
| Comparator | Tirzepatide up to 15 mg | Direct commercial rival | Limited high-dose exposure |
| Evidence role | Claims-based analysis | Decision support | Cannot establish superiority |
The next major evidence milestone would be randomized direct cardiovascular comparison between semaglutide and tirzepatide.
Until then, the appropriate conclusion is narrower but still strategically important: Ozempic has generated a favorable real-world cardiovascular signal versus switching to Mounjaro — not proof that Mounjaro is cardiovascularly inferior.